AVEO Pharmaceuticals, Inc. (AVEO)

0.90
0.02 2.17
NASDAQ
Prev Close 0.92
Open 0.92
Day Low/High 0.88 / 0.92
52 Wk Low/High 0.56 / 3.59
Volume 2.23M
Exchange NASDAQ
Shares Outstanding 160.74B
Market Cap 148.38M
Div & Yield N.A. (N.A)

Latest News

AVEO Pharmaceuticals, Inc. Announces Proposed Public Offering

AVEO Pharmaceuticals, Inc. Announces Proposed Public Offering

AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) ("AVEO" or the "Company"), a biopharmaceutical company seeking to advance targeted medicines for oncology and other unmet medical needs, today announced it has commenced an underwritten public offering of its...

Noteworthy Tuesday Option Activity: AVEO, CARS, WBT

Noteworthy Tuesday Option Activity: AVEO, CARS, WBT

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in AVEO Pharmaceuticals Inc , where a total of 51,729 contracts have traded so far, representing approximately 5.2 million underlying shares. That amounts to about 78% of AVEO's average daily trading volume over the past month of 6.6 million shares.

AVEO Oncology To Present At The H.C. Wainwright Global Life Sciences Conference

AVEO Oncology To Present At The H.C. Wainwright Global Life Sciences Conference

AVEO Oncology (NASDAQ: AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the H.

Lifshitz & Miller LLP Announces Investigation Of AVEO Pharmaceuticals, Inc., CenturyLink, Inc., Inogen, Inc., Mattel, Inc., Spark Therapeutics, Inc., Stamps.com, Inc., Syneos Health, Inc., And Weight Watchers, Inc.

Lifshitz & Miller LLP Announces Investigation Of AVEO Pharmaceuticals, Inc., CenturyLink, Inc., Inogen, Inc., Mattel, Inc., Spark Therapeutics, Inc., Stamps.com, Inc., Syneos Health, Inc., And Weight Watchers, Inc.

NEW YORK, March 22, 2019 /PRNewswire/ -- AVEO Pharmaceuticals, Inc. (AVEO) Lifshitz & Miller announces investigation into possible securities laws violations in connection with the FDA seeking additional survival data concerning tivozanib echoing concerns...

AVEO Reports Full Year 2018 Financial Results And Provides Business Update

AVEO Reports Full Year 2018 Financial Results And Provides Business Update

AVEO Oncology (NASDAQ: AVEO) today reported financial results for the full year ended December 31, 2018 and provided a business update.

Glancy Prongay & Murray LLP Announces Investigation On Behalf Of AVEO Pharmaceuticals, Inc. Investors

Glancy Prongay & Murray LLP Announces Investigation On Behalf Of AVEO Pharmaceuticals, Inc. Investors

Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of AVEO Pharmaceuticals, Inc.

AVEO INVESTOR ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against AVEO Pharmaceuticals, Inc. - AVEO

AVEO INVESTOR ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against AVEO Pharmaceuticals, Inc. - AVEO

NEW YORK, March 7, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of AVEO Pharmaceuticals, Inc.

RM LAW Announces Class Action Lawsuit Against AVEO Pharmaceuticals, Inc.

RM LAW Announces Class Action Lawsuit Against AVEO Pharmaceuticals, Inc.

BERWYN, Pa., March 5, 2019 /PRNewswire/ --  RM LAW, P.

AVEO INVESTOR ALERT: Rosen Law Firm Reminds AVEO Pharmaceuticals, Inc. Investors Of Important Deadline In Securities Class Action Lawsuit - AVEO

AVEO INVESTOR ALERT: Rosen Law Firm Reminds AVEO Pharmaceuticals, Inc. Investors Of Important Deadline In Securities Class Action Lawsuit - AVEO

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AVEO Pharmaceuticals, Inc.

INVESTOR ACTION ALERT: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against AVEO Pharmaceuticals, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

INVESTOR ACTION ALERT: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against AVEO Pharmaceuticals, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AVEO Pharmaceuticals, Inc.

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against AVEO Pharmaceuticals, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against AVEO Pharmaceuticals, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AVEO Pharmaceuticals, Inc.

AVEO Oncology Announces Appointment Of Gregory T. Mayes To Its Board Of Directors

AVEO Oncology Announces Appointment Of Gregory T. Mayes To Its Board Of Directors

AVEO Oncology (NASDAQ: AVEO) today announced the appointment of Gregory T. Mayes to its Board of Directors.

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against AVEO Pharmaceuticals, Inc. - AVEO

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against AVEO Pharmaceuticals, Inc. - AVEO

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of AVEO Pharmaceuticals, Inc.

AVEO Oncology To Present At The 8th Annual SVB Leerink Global Healthcare Conference

AVEO Oncology To Present At The 8th Annual SVB Leerink Global Healthcare Conference

AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 8th Annual SVB Leerink Global Healthcare Conference in New York on Wednesday, February 27, 2019 at 2:30 p.

Figure 2: Progression-Free Survival Per IRC In Patients Receiving Prior IO (Subgroup Analysis) (Graphic: Business Wire)

Figure 2: Progression-Free Survival Per IRC In Patients Receiving Prior IO (Subgroup Analysis) (Graphic: Business Wire)

AVEO Oncology (NASDAQ:AVEO) today announced the presentation of data from the Phase 3 TIVO-3 study of tivozanib (FOTIVDA ®) versus sorafenib in refractory advanced or metastatic renal cell carcinoma (RCC).

AVEO Oncology Announces NDA Timing Update

AVEO Oncology Announces NDA Timing Update

AVEO Oncology (NASDAQ: AVEO) today announced that it has accepted the recommendation of the U.

First Week Of February 15th Options Trading For AVEO Pharmaceuticals (AVEO)

First Week Of February 15th Options Trading For AVEO Pharmaceuticals (AVEO)

Investors in AVEO Pharmaceuticals Inc saw new options begin trading this week, for the February 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AVEO options chain for the new February 15th contracts and identified the following call contract of particular interest.

AVEO Oncology To Present At The 37th Annual J.P. Morgan Healthcare Conference

AVEO Oncology To Present At The 37th Annual J.P. Morgan Healthcare Conference

AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 37th Annual J.

AVEO Oncology To Present TIVO-3 Data At The 2019 ASCO Genitourinary Cancers Symposium

AVEO Oncology To Present TIVO-3 Data At The 2019 ASCO Genitourinary Cancers Symposium

AVEO Oncology (NASDAQ: AVEO) today announced that data from the Phase 3 TIVO-3 study of tivozanib (FOTIVDA ®) versus sorafenib in refractory advanced or metastatic renal cell carcinoma (RCC) will be presented during an oral session at the 2019 American...

Here's a Handful of Small Biotechs Where Insiders Are Buying

Here's a Handful of Small Biotechs Where Insiders Are Buying

Quotient Limited, Iovance Biotherapeutics and AVEO Pharmaceuticals are among the names seeing insider purchases.

AVEO Oncology Announces Immuno-Oncology Clinical Collaboration With AstraZeneca

AVEO Oncology Announces Immuno-Oncology Clinical Collaboration With AstraZeneca

AVEO Oncology (NASDAQ: AVEO) today announced that it has entered into a clinical collaboration with AstraZeneca to evaluate the safety and efficacy of AstraZeneca's IMFINZI ® (durvalumab), a human monoclonal antibody directed against programmed...

AVEO Oncology Announces Extension Of Debt Facility Interest Only Period

AVEO Oncology Announces Extension Of Debt Facility Interest Only Period

AVEO Oncology (NASDAQ:AVEO) today announced a six-month extension to the interest only period under its existing amended and restated loan and security agreement with Hercules Capital, Inc.

2 Small Biotech Stocks That Insiders Are Buying

2 Small Biotech Stocks That Insiders Are Buying

Both names looked poised to go higher as soon as sentiment around the small biotech sector improves.

AVEO Oncology To Present At The 30th Annual Piper Jaffray Healthcare Conference

AVEO Oncology To Present At The 30th Annual Piper Jaffray Healthcare Conference

AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 30th Annual Piper Jaffray Healthcare Conference in New York on Wednesday, November 28, 2018 at 2:30 p.

AVEO Oncology Announces $2M Milestone Payment From EUSA Pharma Related To German Commercialization Of FOTIVDA®

AVEO Oncology Announces $2M Milestone Payment From EUSA Pharma Related To German Commercialization Of FOTIVDA®

AVEO Oncology (NASDAQ: AVEO) today announced the triggering of a $2 million milestone payment to AVEO from EUSA Pharma.

AVEO Reports Third Quarter 2018 Financial Results And Provides Business Update

AVEO Reports Third Quarter 2018 Financial Results And Provides Business Update

AVEO Oncology (NASDAQ:AVEO) today reported financial results for the third quarter ended September 30, 2018 and provided a business update.

July 2019 Options Now Available For AVEO Pharmaceuticals (AVEO)

July 2019 Options Now Available For AVEO Pharmaceuticals (AVEO)

Investors in AVEO Pharmaceuticals Inc saw new options begin trading today, for the July 2019 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 254 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

AVEO Oncology Announces Phase 3 TIVO-3 Trial Of Tivozanib In Renal Cell Carcinoma Meets Primary Endpoint

AVEO Oncology Announces Phase 3 TIVO-3 Trial Of Tivozanib In Renal Cell Carcinoma Meets Primary Endpoint

AVEO Oncology (NASDAQ: AVEO) today announced positive topline results from the primary analysis of the TIVO-3 trial, the Company's Phase 3 randomized, controlled, multi-center, open-label study to compare tivozanib (FOTIVDA ®) to sorafenib in 351 subjects...

TheStreet Quant Rating: D- (Sell)